24-Feb-2026
The Economic Times
The EU-India FTA promises cheaper drugs and medical devices, but India's regulatory framework may hinder patient benefits. Current pricing mechanisms, including market-based ceiling prices and loopholes for fixed-dose combinations, prevent cost reductions from reflecting in retail prices. An urgent overhaul of drug pricing and an independent regulator for procedures are needed to ensure affordability and realize the FTA's full potential.
14-Aug-2025
Focus on the Global South
The Forum for Trade Justice condemns the UK-India CETA for allowing India to make severe concessions that undermine its ability to maintain public health safeguards, control digital data sovereignty, and protect domestic industries, while the promised export gains are minimal or illusory.
9-Jul-2025
The Edge Malaysia
Malaysian CSOs have urged the government to reject the inclusion of the ISDS clause in the RCEP agreement. They warn that ISDS allows foreign investors to sue governments over policies safeguarding public interests like health, workers, and the environment, potentially leading to costly legal battles and large payouts detrimental to national budgets.